Syros Pharmaceuticals, Inc.(NASDAQ : SYRS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Loading SYRS News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.04%||68.55||0.9%||$505.54m|
|REGN||Regeneron Pharmaceuticals, Inc.||5.97%||388.49||2.7%||$332.95m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.69%||127.78||1.9%||$250.96m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.75%||118.30||1.9%||$235.75m|
|NBIX||Neurocrine Biosciences, Inc.||-0.36%||53.40||5.3%||$114.24m|
|BMRN||BioMarin Pharmaceutical Inc.||-0.40%||95.88||4.5%||$113.09m|
|KITE||Kite Pharma, Inc.||-0.68%||82.08||16.6%||$94.29m|
|A||Agilent Technologies, Inc.||-0.70%||55.04||1.5%||$93.33m|
|SRPT||Sarepta Therapeutics, Inc.||4.44%||36.26||19.8%||$82.73m|
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. Its platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. The company focuses on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner in 2012 and is headquartered in Cambridge, MA.